Ciara Curtin writes science features for GenomeWeb and is the editor of the Daily Scan and Careers blogs.
The organoids could be grown to contain cellular features of the original tissue samples, enabling them to better mimic what occurs in the body than two-dimensional cultures.
The classifier, called PurIST, can be applied to various pancreatic cancer sample types and different gene expression platforms, which may improve its clinical applicability.
Genetic testing results increasingly inform clinical decisions, though the inclusion of hereditary risk genes beyond BRCA1, BRCA2, and PALB2 sparked debate.
The vaccine targets multiple proteins that are overexpressed by breast tumors and aims to prevent the disease from developing.
The patient-derived organoids, though, couldn't predict response to a 5-fluorouracil plus oxaliplatin regimen, underscoring more research is needed before clinical use.
In a study, patients with class 3 BRAF mutations were more likely to respond to an anti-EGFR antibody treatment as a first-or second-line therapy.
Treatment biomarkers for small cell lung cancer have been nearly non-existent, but researchers are beginning to find ones that mark PARP inhibitor response.
The program, called Project Facilitate, aims to help oncologists request access to investigational drugs but may only simplify part of the process.
A proteogenomic analysis by a Moffitt Cancer Center-led team uncovered three subtypes of squamous cell lung cancer and treatment approaches to investigate.
A finding that not all BRCA-mutated tumors are likely to respond to PARP inhibitors should make doctors more cautious when prescribing them off label.